MSB

3.06%

$1.01 mesoblast limited

TYPE A OUTCOME AND NOVARTIS PARTNERSHIP, page-5

First 5 Last

Share
Profile

Follow
ces

402 Posts.

30

20/11/20

08:54

Post #: 49008613
Share

Originally posted by vorzaw: ↑

Taken from the report

On November 17, 2020, a Type A meeting was held with the FDA to discuss the review of the BLA for remestemcel-L and a
potential pathway for accelerated approval with a post-approval requirement to conduct an additional randomized controlled study in
patients 12 years and older. At the current time it appears that the FDA review team will not agree to accelerated approval. However,
the definitive outcome of the Type A meeting will not be known until Mesoblast receives the formal minutes which are expected
within 30 days of the meeting. If the current review team does not agree to accelerated approval, Mesoblast will request a further Type
A meeting to initiate the well-established FDA dispute resolution pathway.
Page 35
On November 20, 2020, the Group entered into a worldwide license and collaboration agreement with Novartis for
the development, manufacture and commercialization of remestemcel-L, with an initial focus on the development of the treatment of
acute respiratory distress syndrome (“ARDS”), including that associated with COVID-19. The Group will retain full rights and
economics for remestemcel-L for graft versus host disease, and Novartis has an option to, if exercised, become the commercial
distributor outside of Japan. The Group will receive $50.0 million in proceeds consisting of an upfront payment of $25.0 million
and $25.0 million through the placement of new fully-paid Mesoblast ordinary shares on closing of the license agreement. Closing
of the license agreement is subject to the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust
Improvement Act and certain other conditions. The Group may receive a total of $505.0 million pending achievement of precommercialization milestones for ARDS indications. The Group may receive additional payments post-commercialization of up to
$750.0 million based on achieving certain sales milestones and tiered double-digit royalties on product sales. The Group has not yet
assessed the accounting impact of this agreement

Expand

i see politics in play with the FDA stalling...not at all surprised....novartis now in play with us...they're readiness to invest,for me is far more credible than the silly political FDA game..terrific

MSB Price at posting: $3.27 Sentiment: Buy Disclosure: Held
57 Upvote

0 Great analysis

Reply

Top Stories

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Bitcoin: Current State of Play & Where to Next | Swyftx

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

There are more pages in this discussion • 107 more messages in this thread...

First 5 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.01		Change 0.030(3.06%)		Mkt cap ! $1.153B

Open	High	Low	Value	Volume
$1.01	$1.04	99.0¢	$5.111M	5.050M

Buyers (Bids)

No.	Vol.	Price($)
2	211966	$1.01

Sellers (Offers)

Price($)	Vol.	No.
$1.02	136540	9

View Market Depth

No.	Vol.	Price($)
1	48333	1.005
3	49000	1.000
3	80800	0.995
5	129515	0.990
1	3300	0.985

Price($)	Vol.	No.
1.020	136540	9
1.025	63000	3
1.030	28077	3
1.040	27850	2
1.045	103431	6

Last trade - 16.10pm 16/08/2024 (20 minute delay)

MSB (ASX) Chart

TYPE A OUTCOME AND NOVARTIS PARTNERSHIP, page-5

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Bitcoin: Current State of Play & Where to Next | Swyftx

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

TYPE A OUTCOME AND NOVARTIS PARTNERSHIP, page-5

Top Stories

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Bitcoin: Current State of Play & Where to Next | Swyftx

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News